HighTower Advisors’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.14M | Sell |
13,409
-3,222
| -19% | -$231K | ﹤0.01% | 2154 |
|
|
2026
Q1 | $1.1M | Buy |
16,631
+2,718
| +20% | +$173K | ﹤0.01% | 2119 |
|
|
2025
Q4 | $884K | Buy |
13,913
+1,113
| +9% | +$69.2K | ﹤0.01% | 2210 |
|
|
2025
Q3 | $703K | Buy |
12,800
+2,377
| +23% | +$97.9K | ﹤0.01% | 2355 |
|
|
2025
Q2 | $344K | Sell |
10,423
-929
| -8% | -$32.3K | ﹤0.01% | 2813 |
|
|
2025
Q1 | $456K | Buy |
11,352
+2,029
| +22% | +$93.2K | ﹤0.01% | 2539 |
|
|
2024
Q4 | $439K | Sell |
9,323
-1,481
| -14% | -$76.9K | ﹤0.01% | 2575 |
|
|
2024
Q3 | $568K | Sell |
10,804
-47
| -0.4% | -$2.62K | ﹤0.01% | 2304 |
|
|
2024
Q2 | $586K | Buy |
10,851
+797
| +8% | +$48.1K | ﹤0.01% | 2205 |
|
|
2024
Q1 | $704K | Buy |
10,054
+636
| +7% | +$49.2K | ﹤0.01% | 2031 |
|
|
2023
Q4 | $786K | Buy |
9,418
+550
| +6% | +$19.9K | ﹤0.01% | 1989 |
|
|
2023
Q3 | $261K | Buy |
8,868
+434
| +5% | +$14.5K | ﹤0.01% | 2704 |
|
|
2023
Q2 | $276K | Buy |
8,434
+272
| +3% | +$10.1K | ﹤0.01% | 2623 |
|
|
2023
Q1 | $288K | Hold |
8,162
| – | – | ﹤0.01% | 2481 |
|
|
2022
Q4 | $374K | Sell |
8,162
-2,013
| -20% | -$86.6K | ﹤0.01% | 2322 |
|
|
2022
Q3 | $494K | Sell |
10,175
-19
| -0.2% | -$914 | ﹤0.01% | 2039 |
|
|
2022
Q2 | $400K | Sell |
10,194
-14
| -0.1% | -$564 | ﹤0.01% | 2179 |
|
|
2022
Q1 | $375K | Buy |
10,208
+103
| +1% | +$3.66K | ﹤0.01% | 2357 |
|
|
2021
Q4 | $460K | Buy |
10,105
+74
| +0.7% | +$2.85K | ﹤0.01% | 2218 |
|
|
2021
Q3 | $358K | Buy |
10,031
+31
| +0.3% | +$913 | ﹤0.01% | 2298 |
|
|
2021
Q2 | $198K | Sell |
10,000
-2,000
| -17% | -$47K | ﹤0.01% | 2674 |
|
|
2021
Q1 | $279K | Sell |
12,000
-700
| -6% | -$14.9K | ﹤0.01% | 2354 |
|
|
2020
Q4 | $264K | Hold |
12,700
| – | – | ﹤0.01% | 2017 |
|
|
2020
Q3 | $275K | Hold |
12,700
| – | – | ﹤0.01% | 1880 |
|
|
2020
Q2 | $299K | Hold |
12,700
| – | – | ﹤0.01% | 1739 |
|
|
2020
Q1 | $150K | Hold |
12,700
| – | – | ﹤0.01% | 1867 |
|
|
2019
Q4 | $135K | Sell |
12,700
-74
| -0.6% | -$760 | ﹤0.01% | 2049 |
|
|
2019
Q3 | $145K | Hold |
12,774
| – | – | ﹤0.01% | 2118 |
|
|
2019
Q2 | $143K | Buy |
12,774
+74
| +0.6% | +$714 | ﹤0.01% | 2119 |
|
|
2019
Q1 | $103K | Hold |
12,700
| – | – | ﹤0.01% | 2059 |
|
|
2018
Q4 | $80K | Hold |
12,700
| – | – | ﹤0.01% | 1990 |
|
|
2018
Q3 | $125K | Buy |
+12,700
| New | +$102K | ﹤0.01% | 2030 |
|
Other funds holding CYTK
ACA
HighTower Advisors's CYTK Position: Q2 2026 in Review
HighTower Advisors reduced its Cytokinetics (CYTK) stake by 19% in Q2 2026, selling an estimated $231K and leaving 13,409 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.
HighTower Advisors first reported a position in CYTK in Q3 2018 and has held it in 32 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- HighTower Advisors held 13,409 shares of Cytokinetics worth $1.14M as of Q2 2026.
- HighTower Advisors sold 3,222 Cytokinetics shares in Q2 2026, an estimated $231K.
- Cytokinetics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2154 holding.
- HighTower Advisors first reported a position in Cytokinetics in Q3 2018 and has held it in 32 quarters since.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.